Drugs / iExosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03608631 | Jan 2021 → Apr 2027 expected | pancreatic ductal adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iExosomes | “This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic...” NCT03608631 ↗ |
| Action | Inhibit | “mesenchymal stem cell (MSC)-derived exosomes loaded with siRNA against KrasG12D” NCT03608631 ↗ |
| Modality | Small interfering RNA (siRNA) | “mesenchymal stem cell (MSC)-derived exosomes loaded with small interference RNA (siRNA) against KrasG12D (iExosomes)” NCT03608631 ↗ |
| Route | Intravenous | “Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA intravenously (IV) over 15-20 minutes on days 1, 4, and 10.” NCT03608631 ↗ |
| Target | KRAS | “siRNA against KrasG12D” NCT03608631 ↗ |